Evidence map›Paper›PMID 36618786›Full record

ArticleAnnals of translational medicine2022

Targeting chromosome 12q amplification in relapsed glioblastoma: the use of computational biological modeling to identify effective therapy-a case report.

Michael P Castro, Negar Khanlou, Aria Fallah, Anusha Pampana, Aftab Alam, Deepak Anil Lala, Kunal Ghosh Ghosh Roy, Anish Raju R Amara, Annapoorna Prakash, Divya Singh and 3 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Michael P CastroBeverly Hills Cancer Center and Personalized Cancer Medicine, PLLC, Beverly Hills, CA, USA.
Negar KhanlouDepartment of Pathology, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA.
Aria FallahDepartment of Neurosurgery, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA.
Anusha PampanaCellworks Group, Inc., S. San Francisco, CA, USA.
Aftab AlamCellworks Group, Inc., S. San Francisco, CA, USA.
Deepak Anil LalaCellworks Group, Inc., S. San Francisco, CA, USA.
Kunal Ghosh Ghosh RoyCellworks Group, Inc., S. San Francisco, CA, USA.
Anish Raju R AmaraCellworks Group, Inc., S. San Francisco, CA, USA.
Annapoorna PrakashCellworks Group, Inc., S. San Francisco, CA, USA.
Divya SinghCellworks Group, Inc., S. San Francisco, CA, USA.
Liptimayee BehuraCellworks Group, Inc., S. San Francisco, CA, USA.
Ansu KumarCellworks Group, Inc., S. San Francisco, CA, USA.
Shweta KapoorCellworks Group, Inc., S. San Francisco, CA, USA.
Cellworks Research (India) · INRonald Reagan UCLA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Relapsed glioblastoma (GBM) is often an imminently fatal condition with limited therapeutic options. Computation biological modeling, i.e., biosimulation, of comprehensive genomic information affords the opportunity to create a disease avatar that can be interrogated Case Description: We report the outcome of a GBM patient with chromosome 12q amplification who achieved substantial disease remission from a novel therapy using this approach. Following next generation sequencing (NGS) was performed on the tumor specimen. Mutation and copy number changes were input into a computational biologic model to create an avatar of disease behavior and the malignant phenotype. Conclusions: Biosimulation has utility to identify active treatment combinations, stratify treatment options and identify investigational agents relevant to patients' comprehensive genomic abnormalities. Additionally, the combination of abemaciclib and nelfinavir appear promising for GBM and potentially other cancers harboring chromosome 12q amplification.

Indexed as

biosimulationcase reportchromosome 12q amplificationComputational biological modeling (CBM)glioblastoma (GBM)

Identifiers

PMID36618786
PMCPMC9816820
OpenAlexW4312115988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.